Clifford Chance

Pharma companies and antitrust in China: Part two – anti-competitive behaviour, abuse of dominance and enforcement trends

30 June 2011

In this second of two articles exploring the impact of China's antitrust regime on the pharmaceutical industry, we consider in more detail how the day-to-day operations of pharmaceutical companies are affected by China's competition regime, and highlight certain commercial practices that may attract the attention of the enforcement authorities.

Download PDF